UNLABELLED The extra domain B of fibronectin (ED-B) is a marker of tumor angiogenesis. The human monoclonal antibody (mAb) L19-SIP (approximately 80 kDa; SIP is "small immunoprotein") has been selected for targeting of ED-B. The aim of this study was to evaluate the potential of radioimmunotherapy (RIT) with L19-SIP, either alone or in combination with cetuximab, for treatment of head and neck ...

OBJECTIVE(S) In this work a new possible agent for radiosynovectomy has been targeted for articular pain palliation. MATERIALS AND METHODS Lu-177 of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3 sample with thermal neutron flux of 4 × 10(13) n.cm(-2).s(-1). The product was converted into chloride form which was further used for labeling of (177)Lu-phytate complex...

The neurotensin receptor (NTS1) has emerged as an interesting target for molecular imaging and radiotherapy of NTS-positive tumors due to the overexpression in a range of tumors. The aim of this study was to develop a 177Lu-labeled NTS1 radioligand, its application for radiotherapy in a preclinical model and the imaging of therapy success by small-animal positron emission tomography (µPET) usin...

The purpose of this study was to investigate the influence of the Ordered Subsets Expectation Maximization (OSEM) reconstruction updates implemented in the 177Lu SPECT/CT imaging processing in molecular radiotherapy. A NEMA IEC Body PhantomTM was used to quantify activity in refillable spheres of five different sizes. Images were obtained with a hybrid dual-head SPECT-CT imaging system (Symbia ...

Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the group of receptor-avid peptide used in the PRRT are the analogues of somatostatin (SST) connected to...

The lack of robust radiobiological data hampers the further optimization emerging 177Lu-PSMA-directed radioligand therapy (RLT). This study aims to explore several conventional parameters in assessment outcomes tumor and normal organs at risk (OARs) for castration-resistant prostate cancer (CRPC) patients. 20 patients received a median 3 (range 1–6, totally 86 cycles) 177Lu-PSMA-617 RLT were re...